Indications |
Oral Nausea and vomiting Adult: As hydrochloride: 50 mg up to tid, up to 200 mg/day. For prevention of motion sickness, 1st dose should be given 30 min before travelling. Child: 6-12 yr: As hydrochloride: 25 mg up to tid. For prevention of motion sickness, 1st dose should be given 30 min before travelling. Renal impairment: Dose reductions may be needed. Hepatic impairment: Avoid in severe liver disease. Parenteral Treatment and prophylaxis of motion sickness Adult: As lactate: 50 mg IV/IM every 4-6 hr. 1st dose should be given 30 min before travelling. Child: As lactate: 25 mg IV/IM up to tid. For prevention of motion sickness, 1st dose should be given 30 min before travelling. Renal impairment: Dose reductions may be needed. Hepatic impairment: Avoid in severe liver disease. Parenteral Prophylaxis of postoperative nausea and vomiting Adult: As lactate: 50 mg up to tid, may be given via IV or IM admin. 1st dose should be given 20 min before anticipated end of surgery. Max: 200 mg/24 hr. Child: 6-12 yr: As lactate: 25 mg up to tid, may be given via IV or IM admin. 1st dose should be given 20 min before anticipated end of surgery. Max: 50 mg tid. Renal impairment: Dose reductions may be needed. Hepatic impairment: Avoid in severe liver disease. Special Populations: Prevention of motion sickness: Give 30 min before traveling. Incompatibility: Cyclizine lactate may be incompatible with oxytetracycline hydrochloride, chlortetracycline hydrochloride, benzylpenicillin and solutions with a pH ≥6.8. Incompatibility: Cyclizine lactate may be incompatible with oxytetracycline hydrochloride, chlortetracycline hydrochloride, benzylpenicillin and solutions with a pH ≥6.8. |
Contraindications |
Premature or full-term neonates. |
Warnings / Precautions |
Angle closure glaucoma; urinary retention; prostatic hypertrophy; pyloroduodenal obstruction; epilepsy, severe CV disorders; known or suspected QT interval prolongation; hypokalaemia or other electrolyte imbalances; asthma; hepatic impairment. May impair ability to drive or operate machinery. Tolerance with prolonged use. Broken or eczematous skin (topical use). Pregnancy and lactation. Elderly. Children <6 yr. Dependence. |
Adverse Reactions |
CNS depression e.g. drowsiness to deep sleep, lassitude, dizziness and incoordination. Headache, psychomotor impairment, dry mouth, thickening of mucous secretions, blurred vision, difficult or painful urination, constipation and increased gastric reflux. Occasionally, GI disturbances, palpitations and arrhythmias. Rashes and hypersensitivity reactions. Blood dyscrasias (rare). Convulsions, sweating, myalgia, paraesthesias, extrapyramidal effects, tremor, sleep disturbances, tinnitus, hypotension and hair loss. |
Overdose Reactions |
Dry mouth, blurred vision, tachycardia, urinary retention, drowsiness, dizziness, inco-ordination, ataxia, weakness, hyperexcitability, disorientation, impaired judgement, hallucinations, hyperkinesia, extrapyramidal motor disturbances, convulsions, hyperpyrexia and respiratory depression. Gastric lavage followed by supportive measures for respiration and circulation. |
Drug Interactions |
Enhanced sedative effects of alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives, antipsychotics. Additive antimuscarinic actions with other antimuscarinic drugs and some antidepressants (TCAs and MAOIs). May mask ototoxicity symptoms caused by aminoglycoside antibiotics. See Below for More cyclizine Drug Interactions |
Mechanism of Actions |
Cyclizine is a sedative antihistamine with antimuscarinic activity. Onset: Within 2 hr upon GI absorption. Duration: Approximately 4 hr. Absorption: Absorbed from the GI tract. Metabolism: Hepatically metabolised to relatively inactive metabolite. Excretion: Plasma elimination half-lives of 20 hr. |
ATC Classification |
R06AE03 - cyclizine ; Belongs to the class of piperazine derivatives used as systemic antihistamines. |
Available As |
|
Cyclizine
Post Review about Cyclizine Click here to cancel reply.
Cyclizine Containing Brands
Cyclizine is used in following diseases
Drug - Drug Interactions of Cyclizine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.